Van Lanschot Kempen

Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors

Retrieved on: 
Tuesday, October 10, 2023

Renovaro recently announced a definitive agreement to combine with the advanced AI Company GEDi Cube Intl Ltd. GEDiCube intends to rebrand as Renovaro AI, as announced on September 29, 2023 .

Key Points: 
  • Renovaro recently announced a definitive agreement to combine with the advanced AI Company GEDi Cube Intl Ltd. GEDiCube intends to rebrand as Renovaro AI, as announced on September 29, 2023 .
  • Both Leni and Ruud bring extensive, high-level experience in finance and business.
  • She also holds several advisory roles, including the Capital Market Committee of the Dutch regulator, the Authority for the Financial Markets.
  • Ruud Hendriks brings over 35 years of experience in the asset management industry, having held senior roles at some of the most established financial institutions.

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

Retrieved on: 
Friday, June 9, 2023

The Company did not receive any proceeds from the Offering.

Key Points: 
  • The Company did not receive any proceeds from the Offering.
  • Jefferies and SVB Securities acted as joint book-running managers for the Offering.
  • 1 to the Form F-1, declared effective by the SEC on April 24, 2023.
  • Cantor Fitzgerald & Co. and Van Lanschot Kempen N.V. acted as financial advisers to the Company.

SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 15.78 MILLION IN AN EQUITY PLACEMENT

Retrieved on: 
Tuesday, April 25, 2023

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: "We are very pleased to announce the closing of this financing round, despite challenging market conditions.

Key Points: 
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: "We are very pleased to announce the closing of this financing round, despite challenging market conditions.
  • EUR 15.2 million of which EUR 12.2 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024;
    (ii)   Preparing the PMA (Pre-Market Approval) filing and review, with planned submission to the FDA in H2 2023.
  • EUR 9.9 million of which EUR 5.4 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024.
  • EUR 2.2 million of which EUR 0.7 million has been spent up to YE 2022 with the remainder to be spent from 2023 until 2025.

SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT AND AMENDS CERTAIN EXISTING LOAN AGREEMENTS

Retrieved on: 
Monday, April 24, 2023

EUR 9.9 million of which EUR 5.4 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024.

Key Points: 
  • EUR 9.9 million of which EUR 5.4 million has been spent up to YE 2022 with the remainder to be attributed over 2023/2024.
  • (i)   Interest expense and a partial repayment of the loan facility with Kreos Capital (total loan cost of EUR 2.4 million up to Q1 2024), resulting from amendments to the above loan agreement, subject to certain conditions;
    (ii)   General corporate and working capital purposes.
  • The Offering shall be structured as a private placement of new shares and subscription rights via an accelerated bookbuilding, which will commence immediately.
  • Trading in Sequana Medical shares on Euronext Brussels will be suspended during the bookbuilding period.

Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update

Retrieved on: 
Friday, April 14, 2023

LUND, Sweden, April 14, 2023 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023.

Key Points: 
  • LUND, Sweden, April 14, 2023 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023.
  • All interested parties are invited to participate in a telephone conference, which will include a presentation of the year-end results and a business update, on the same date at 14:00 CET/8:00am EST.
  • The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
  • Link to presentation
    To participate in the telephone conference, please use the dial-in details provided below:
    April 25, 2023    Van Lanschot Kempen Life Sciences Conference 2023, Amsterdam
    May 11, 2023 Erik Penser Company Day, Malmö
    May 25, 2023    Erik Penser Company Day, Stockholm
    Aug 24, 2023    Erik Penser Company Day, Stockholm
    Sept 7, 2023    CITI Annual BioPharma Conference, Boston
    Sept 11, 2023    MorganStanley Global Healthcare Conference, NYC
    Sept 14, 2023    Pareto Annual Healthcare Conference, Stockholm
    Nov 22, 2023    Ökonomisk Ugebrev Life Science Event, Copenhagen

Kempen Capital Management disapproves recent Board decisions at Fujitec

Retrieved on: 
Thursday, June 30, 2022

Kempen Capital Management N.V. (Kempen) disapproves recent Board decisions at Fujitec Co., Ltd. (Fujitec).

Key Points: 
  • Kempen Capital Management N.V. (Kempen) disapproves recent Board decisions at Fujitec Co., Ltd. (Fujitec).
  • A copy of the open letter can be found here: link to open letter
    This document has been prepared by Kempen Capital Management N.V. (Kempen) for the benefit and use of the original recipients.
  • As of 31 December 2021, Kempen Capital Management had a total of 91.9 billion in client assets under management.
  • Kempen Capital Management N.V., part of Van Lanschot Kempen N.V., is a specialist and independent wealth manager.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022

These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022

WARSAW, Poland, Jan. 14, 2022 /PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and unexplored protein targets to treat multiple incurable diseases, announces the appointment of Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński to its Supervisory Board. These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

Kempen Capital Management Issues Open Letter to Fujitec’s Board of Directors

Retrieved on: 
Wednesday, January 12, 2022

This document has been prepared by Kempen Capital Management N.V. (Kempen) for the benefit and use of the original recipients.

Key Points: 
  • This document has been prepared by Kempen Capital Management N.V. (Kempen) for the benefit and use of the original recipients.
  • As of 30 June 2021, Kempen Capital Management had a total of 88.3 billion in client assets under management.
  • Kempen Capital Management, part of Van Lanschot Kempen NV, is a specialist and independent wealth manager.
  • Kempen Capital Management (UK) Ltd is licensed as a manager and subject to supervision by the Financial Conduct Authority.

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Tuesday, November 9, 2021

WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (IO Biotech) today announced the closing of its initial public offering of 8,222,500 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,072,500 additional shares of common stock,] at the initial public offering price of $14.00 per share.

Key Points: 
  • WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (IO Biotech) today announced the closing of its initial public offering of 8,222,500 shares of its common stock, including the exercise in full by the underwriters option to purchase 1,072,500 additional shares of common stock,] at the initial public offering price of $14.00 per share.
  • The gross proceeds to IO Biotech, before deducting underwriting discounts and commissions and offering expenses, were approximately $115.1 million.
  • The shares began trading on The Nasdaq Global Market November 5, 2021, under the symbol "IOBT."
  • IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform.